July 10, 2024
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study
Riccardo Perfetti, MD, PhD, Evan Bailey, MD, Stella Wang, MPH, MS, Richard Mills, PhD, Ramon Mohanlal, MD, PhD, MBA, Shoshana Shendelman, PhD
Journal of Clinical Pharmacology
May 4, 2020
Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes
Andrea Cortese, Yi Zhu, Adriana P. Rebelo, Sara Negri, Steve Courel, Lisa Abreu, Chelsea J. Bacon, Yunhong Bai, Dana M. Bis-Brewer, Enrico Bugiardini, Elena Buglo, Matt C. Danzi, Shawna M. E. Feely, Alkyoni Athanasiou-Fragkouli, Nourelhoda A. Haridy, Inherited Neuropathy Consortium, Rosario Isasi, Alaa Khan, Matilde Laurà, Stefania Magri, Menelaos Pipis, Chiara Pisciotta, Eric Powell, Alexander M. Rossor, Paola Saveri, Janet E. Sowden, Stefano Tozza, Jana Vandrovcova, Julia Dallman, Elena Grignani, Enrico Marchioni, Steven S. Scherer, Beisha Tang, Zhiqiang Lin, Abdullah Al-Ajmi, Rebecca Schüle, Matthis Synofzik, Thierry Maisonobe, Tanya Stojkovic, Michaela Auer-Grumbach, Mohamed A. Abdelhamed, Sherifa A. Hamed, Ruxu Zhang, Fiore Manganelli, Lucio Santoro, Franco Taroni, Davide Pareyson, Henry Houlden, David N. Herrmann, Mary M. Reilly, Michael E. Shy, R. Grace Zhai, Stephan Zuchner
Nature Genetics
April 8, 2024
A Selective Aldose Reductase Inhibitor (AT-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
2024 American College of Cardiology Annual Scientific Session
July 9, 2024
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients with Diabetic Cardiomyopathy
James L. Januzzi, MD, Javed Butler, MD, MPH, MBA, Stefano Del Prato, MD, Justin A. Ezekowitz, MB, BCH, Nasrien E. Ibrahim, MD, MPH, Carolyn S.P. Lam, MBBS, PHD, Gregory D. Lewis, MD, Thomas H. Marwick, MBBS, PHD, MPH, Riccardo Perfetti, MD, PHD, Julio Rosenstock, MD, Scott D. Solomon, MD, W.H. Wilson Tang, MD, Faiez Zannad, MD, PHD
Journal of the American College of Cardiology
November 2, 2022
Aldose Reductase Inhibition by AT-001 Alleviates Fibrosis and Adverse Remodelling in Diabetic Cardiomyopathy by Reducing Myocardial Fatty Acid Oxidation
Presented by Keshav Gopal, Qutuba G Karwi, S. Amirhossein Tabatabaei-Dakhili, Cory S Wagg, Liyan Zhang, Qiuyu Sun, Christina T Saed, Sai Panidarapu, Riccardo Perfetti, Ravichandran Ramasamy, John R Ussher, Gary D Lopaschuk
American Heart Association (AHA) Scientific Session 2022
Diabetic Cardiomyopathy Is Associated with Worsening Quality of Life Long Before the Development of Overt Heart Failure: Lessons from the Baseline Analysis of the ARISE-HF Trial
Presented by Alessia Urbinati, Riccardo Perfetti, Stella Wang, Sariah Persaud, Shoshana Shendelman, James L Januzzi Jr.
American Heart Association (AHA) Scientific Session 2022